Estefanía Rojo-Bustamante

GPR55: A therapeutic target for Parkinson's disease?

Marta Celorrio, Estefanía Rojo-Bustamante, Diana Fernández‐Suárez et al. · Neuropharmacology · 2017 · 102 citations

Functional Selectivity, Medicine, Neurochemical Biomarkers +3

Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson’s disease

Marta Celorrio, Diana Fernández‐Suárez, Estefanía Rojo-Bustamante et al. · Brain Behavior and Immunity · 2016 · 69 citations

Neurodegenerative Diseases, Hydrolase Inhibition, Biochemistry +6

Pharmacologic antagonism of dopamine receptor D3 attenuates neurodegeneration and motor impairment in a mouse model of Parkinson's disease

Daniela Elgueta, Marta Aymerich, Francisco Contreras et al. · Neuropharmacology · 2016 · 62 citations

Motor Impairment, Medicine, Neuropharmacology +8

Neuroprotective Effect of JZL184 in MPP+-Treated SH-SY5Y Cells Through CB2 Receptors

Marta Aymerich, Estefanía Rojo-Bustamante, Carmen Molina et al. · Molecular Neurobiology · 2015 · 44 citations

Cb2 Receptors, Mpp+-treated Sh-sy5y Cells, Medicine +8

The expression of cannabinoid type 1 receptor and 2-arachidonoyl glycerol synthesizing/degrading enzymes is altered in basal ganglia during the active phase of levodopa-induced dyskinesia

Estefanía Rojo-Bustamante, Miguel Angel Abellanas, Pedro Clavero et al. · Neurobiology of Disease · 2018 · 27 citations · Full text

Cannabis Use, Medicine, Levodopa-induced Dyskinesia +12